From spinal cord injury to Parkinson’s disease and Alzheimer’s, researchers continue to uncover powerful ways the body can repair itself—especially when supported by targeted therapies. This week’s featured studies spotlight how the nervous system’s healing potential is being influenced by developments in cell-based treatments, immune regulation, and mitochondrial signaling.
We explore how iPSC-derived therapies are progressing from lab models to clinical trials, offering new hope for conditions like Parkinson’s. In spinal cord injury research, modulating inflammatory pathways appears to shift microglia from harmful to healing states—supporting regeneration and motor recovery. And in Alzheimer’s disease, the mitochondrial peptide Humanin shows promise in shielding neurons from oxidative stress and cellular damage, with implications for slowing cognitive decline.
1. iPSC-based cell replacement therapy: from basic research to clinical application
Induced pluripotent stem cells (iPSCs) are reshaping the future of regenerative medicine. This review highlights how iPSC-based therapies—especially in Parkinson’s disease—are moving from lab research to clinical application. With an emphasis on safety, precision, and collaboration across sectors, the field continues to advance toward therapies that aim to restore lost function and improve patient outcomes..
2. ELAVL1-mediated USP29 mRNA degradation activates TAK1 driving M1 microglial polarization and neural stem cell differentiation dysregulation in spinal cord injury
In spinal cord injury, ELAVL1 degrades USP29 mRNA, unleashing TAK1 activity that drives harmful M1 microglial states and disrupts neural stem cell (NSC) neuron formation. Blocking ELAVL1 stabilizes USP29, restrains TAK1, shifts microglia to a reparative M2 profile, and supports NSC-driven neurogenesis—leading to better motor recovery and spinal repair in rats.
3. The neuroprotective role of Humanin in Alzheimer’s disease: The molecular effects
Humanin, a peptide derived from mitochondria, protects the brain by reducing oxidative stress, inflammation, and neuron death in Alzheimer’s disease. Its ability to block amyloid toxicity and support cellular repair makes it a promising candidate for slowing cognitive decline.
If you’d like to stay informed of the latest publications and breakthroughs in neuron regeneration, join our email newsletter to the right (or below on mobile). We send out weekly updates with the latest papers and studies, as well as podcast episodes with the people driving Neuroregenerative breakthroughs.
